1. |
Badalà F, Fioretto M, Macrì A. Effect of topical 0.1% indomethacin solution versus 0.1% fluorometholon acetate on ocular surface and pain control following laser subepithelial keratomileusis (LASEK)[J]. Cornea, 2004, 23(6):550-553.
|
2. |
Fantes FE, Hanna KD, Waring GO, et al. Wound healing after exicmer laser keratiomileusis (photorefractive Keratectomy) in monkeys[J]. Arch Ophthalmol, 1990, 108(5):665-675.
|
3. |
Kim SJ, Flach AJ, Jampol LM. Nonsteroidal anti-inflammatory drugs in ophthalmology[J]. Surv Ophthalmol, 2010, 55(2):108-133.
|
4. |
Donnenfeld ED, Donnenfeld A. Global experience with xibrom (bromfenac ophthalmic solution) 0.09%:the first twice-daily ophthalmic nonsteroidal anti-inflammatory drug[J]. Int Ophthalmol Clin, 2006, 46(4):21-40.
|
5. |
Group Eye Disease Study Research Age-related. Risk factors associated with age-related nuclear and cortical cataract:a case-control study in the Age-Related Eye Disease Study, AREDS Report No. 5[J]. Ophthalmology, 2001, 108(8):1400-1408.
|
6. |
Abelson MB, Butrus SI, Weston JH. Aspirin therapy in vernal conjunctivitis[J]. Am J Ophthalmol, 1983, 95(4):502-505.
|
7. |
Abelson MB, Schaefer K. Conjunctivitis of allergic origin:immunologic mechanisms and current approaches to therapy[J]. Surv Ophthalmol, 1993, 38(Suppl):115-132.
|
8. |
Wang XJ, Wong SH, Givergis R, et al. Evaluation of analgesic efficacy of bromfenac sodium ophthalmic solution 0.09% versus ketorolac tromethamine ophthalmic solution 0.5% following LASEK or Epi-LASIK[J]. Clin Ophthalmol, 2011, 5(4):1451-1457.
|
9. |
Guex-Crosier Y. Non-steroidal anti-inflammatory drugs and ocular inflammation[J]. Klin Monbl Augenheilkd, 2001, 218(5):305-308.
|
10. |
Bakalyan GA, Deshmukh HM, Patterson H, et al. Concentrations of radioactivity in ocular tissues after a single topical dose of 14C-bromfenac ophthalmic solution[C]//Proceedings of the American Society of Cataract & Refractive Surgery (ASCRS) Meeting. San Francisco, CA:American Society of Cataract & Refractive Surgery, 2006:227.
|
11. |
Mcnamara TR, Baklayan GA, Deshmukh HM, et al. Concentrations of radioactivity in ocular tissues after a single topical dose of 14C-bromfenac ophthalmic solution[C]//Proceedings of the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. Ft. Lauderdale:Association for Research in Vision and Ophthalmology, 2006:5086.
|
12. |
Ogawa T, Miyake K, Mcnamara TR, et al. Pharmacokinetic profile of topically applied bromfenac sodium ophthalmic solution 0.1% in subijects undergoing cataract surgery[C]//Proceedings of the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. Ft. Lauderdale:Association for Research in Vision and Ophthalmology, 2006:687.
|
13. |
Masuda K, Fukado Y, Shimizu H, et al. Effect of bromfenac sodium ophthalmic solution on inflammation following intraocular lens implantation[J]. Ganka Rinsho Iho (Jpn Rev Clin Ophthalmol), 1997, 91(2):745-750.
|
14. |
Kawaguchi T, Kida T, Nemoto S, et al. Effect of bromfenac sodium ophthalmic solution on ocular inflammation and corneal epithelial barrier function following cataract surgery[J]. Folia Ophthalmol Jpn, 2003, 54(5):276-279.
|
15. |
Takamatsu F, Shiroyama N, Saito Y, et al. Efficacy and adverse effects of bromfenac ophthalmic solution following cataract surgery[J]. Rinsho Ganka (Jpn J Clin Ophthalmol), 2003, 11(8):57.
|
16. |
Ohara K, Ohkuba A, Miyamoto T, et al. Effect of bromfenac sodium on postoperative inflammation[J]. Jpn J Catarac Refract Surg, 2004, 18(5):1-21.
|
17. |
Stewart RH, Walters TR, Cooke DL, et al. Integrated results from two phase Ⅲ studies of topical xibromt 0.1%, an investigational NSAID for post-cataract surgery inflammation[C]//Proceedings of the 108th Annual American Academy of Ophthalmology Meeting. New Orleans, LA:American Academy of Ophthalmology, 2004:22-24.
|
18. |
Donnenfeld ED, Holland EJ, Stewart RH, et al. Topical xibrom 0.1%, an investigational NSAID for post-cataract surgery inflammation, markedly decreases inflammation[C]//Proceedings of the American Society of Cataract & Refractive Surgery (ASCRS) Meeting. Washington, DC:American Society of Cataract & Refractive Surgery, 2005:650-653.
|
19. |
Donnenfeld ED, Holland EJ, Stewart RH, et al. Topical xibromt 0.09% significantly and rapidly decreased post-cataract surgery inflammation and reduced ocular pain[J]. Invest Ophthalmol Vis Sci, 2005, 25(3):46.
|
20. |
Miyake-Kashima M, Takano Y, Tanaka M, et al. Comparison of 0.1% bromfenac sodium and 0.1% pemirolast potassium for the treatment of allergic conjunctivitis[J]. Jpn J Ophthalmol, 2004, 48(6):587-590.
|
21. |
Usui M, Masuda K. Effect of bromfenac sodium (AHR-10282B) eye drops on anterior uveitis[J]. Ganka Rinsho Iho (J Rev Clin Ophthalmol), 1997, 91(4):39-44.
|
22. |
Elman MJ, Raden RZ, Sloan MD, et al. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema[J]. Ophthalmology, 2008, 115(9):1449.
|
23. |
The DAMAD Study Group. Effect of aspirin alone, aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial[J]. Diabetes, 1989, 38(4):491-498.
|
24. |
Benson SE, Ratclliffe S, Van Raders P, et al. A randomized comparison of parecoxib/valdecoxib and placebo for the prevention of cystoid macular edema after scleral buckling surgery[J]. Retina, 2009, 29(3):387-394.
|
25. |
Bhagat N, Grigorian RA, Tutela A, et al. Diabetic macular edema:pathogenesis and treatment[J]. Surv Ophthalmol, 2009, 54(1):1-32.
|
26. |
Bielory L, Friedlaender MH. Allergic conjunctivitis[J]. Immunol Allergy Clin North Am, 2008, 28(1):43-58.
|
27. |
Brooks CD, Karl KJ. Hay fever treatment with combined antihistamine and cyclooxygenase-inhibiting drugs[J]. J Allergy Clin Immunol, 1988, 81(6):1110-1117.
|
28. |
Brooks CD, Nelson AL, Metzler C. Effect of flurbiprofen, a cyclooxygenase inhibiting drug, on induced allergic rhinitis[J]. J Allergy Clin Immunol, 1984, 73(5 Pt 1):584-589.
|
29. |
许艳, 张丰菊. 非甾体类抗炎药在角膜屈光手术后的应用[J]. 大连医科大学学报, 2012, 34(2):189-193.
|